MSD and Turning Point turn to China for big deals in May
Danni Yin · 06/30/2022
The biotech deal making space in May 2022 saw Chinese drugmakers licensing out their assets for as much as a billion dollars. MSD and Turning Point Therapeutics gained China-originated cancer drugs in deals worth $2.63 billion.
April licensing trends show Chinese biotechs expanding beyond oncology
Minhua Chu · 05/26/2022
From March 2021 to April 2022, there have been seven deals in ophthalmology. Ophthalmic drugs have become an important target of in-licensing deals in China.
Adagene-Sanofi’s $2.5B deal tops March deals in China
Minhua Chu · 04/28/2022
Several early-stage out-licensing deals inked by Chinese biotech firms to carry their in-house technology platforms and pipelines to the global market marked the dealmaking space of March 2022.
Huadong Medicine lands three in-licensing deals in one month
Minhua Chu · 03/21/2022
Huadong Medicine announced a series of three in-licensing deals with a combined value of $1.667 billion, pushing the total deal value for February to $1.883 billion, edging over the $1.681 billion the previous month.
Chinese drug developer looks to enter the U.S. market through out-licensing deals
Minhua Chu · 02/14/2022
In the first month of 2022, 16 licensing deals related to innovative drugs were announced, including eight in-licensing, four out-licensing and four domestic deals.
Licensing moves towards early-stage assets in 2021
Danni Yin · 01/14/2022
Early-stage assets made up half of the licensing deals in 2021, up 10% from the previous year.
2021 wraps up with multi-billion dollar deals
Minhua Chu · 01/07/2022
In November and December 16 and 21 licensing deals were reached, respectively. December boasted the second highest number of deals for the year, including 18 in-licensing deals from overseas, seven out-licensed deals and 12 deals between Chinese pharmaceutical firms.
Hansoh’s siRNA therapeutics deals stand out in October
Minhua Chu · 11/19/2021
Chinese drugmakers struck 14 licensing deals in October with five of them exceeding $100 million. Hansoh Pharma announced two big deals worth nearly $2 billion in total to mark its foray into siRNA therapeutics.
September sees the most licensing deals of the year so far
Minhua Chu · 10/28/2021
Among the 22 deals Chinese drugmakers closed in September, 14 were worth $2.566 billion. Everest Medicines and Innovent Biologics dominated the dealmaking space with deals worth $1.06 billion and $529 million, respectively, representing 62% of the total value of all disclosed deals.
Copyright © 2016-2022 PharmaDJ .All Rights Reserved.   Suggestions and feedback:   Record/License No.:沪ICP备17054709号-1  
About PharmaDJ | Subscription | Contact Us | Copyright Statement